04:25 PM EDT, 05/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

Following the solid rally in IDXX shares in the last two weeks, after the company announced solid Q1 earnings, we lift our target price to $563 from $528, 41.5x our 2026 EPS view, a discount to IDXX's five-year historical forward P/E average of 53.4x. We increase our 2025 estimate to $12.23 from $12.15 and raise our 2026 EPS to $13.58 from $13.41. We continue to be bullish on shares of IDEXX Laboratories ( IDXX ) as we anticipate the solid momentum seen in the first quarter of 2025 to continue through the remainder of 2025. We expect the newly launched (Q4) IDEXX ( IDXX ) inVue analyzer sales to grow throughout the year as pet diagnostics remain resilient notwithstanding uncertainties in the macroeconomic environment. Despite declines in clinical visits in the U.S., IDXX has so far managed to increase its CAG Diagnostics recurring revenue as pet owners continue to prioritize their pet's health, with nearly half of clinical visits including some kind of diagnostic testing (a trend we expect to continue).